Price Don’t Lie: Xenon Pharmaceuticals Inc Stock Is Crashing Now

Price Don't Lie: Xenon Pharmaceuticals Inc Stock Is Crashing Now

The stock of Xenon Pharmaceuticals Inc (NASDAQ:XENE) is a huge mover today! About 20,591 shares traded hands. Xenon Pharmaceuticals Inc (NASDAQ:XENE) has risen 8.54% since March 11, 2016 and is uptrending. It has outperformed by 3.09% the S&P500.
The move comes after 6 months negative chart setup for the $140.39M company. It was reported on Oct, 14 by Barchart.com. We have $7.41 PT which if reached, will make NASDAQ:XENE worth $14.04M less.

Analysts await Xenon Pharmaceuticals Inc (NASDAQ:XENE) to report earnings on November, 8. They expect $-0.47 earnings per share, down 74.07% or $0.20 from last year’s $-0.27 per share. After $-0.42 actual earnings per share reported by Xenon Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 11.90% negative EPS growth.

Xenon Pharmaceuticals Inc (NASDAQ:XENE) Ratings Coverage

Out of 3 analysts covering Xenon Pharmaceuticals (NASDAQ:XENE), 2 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 67% are positive. Xenon Pharmaceuticals has been the topic of 8 analyst reports since August 11, 2015 according to StockzIntelligence Inc. Canaccord Genuity maintained the shares of XENE in a report on Tuesday, August 11 with “Buy” rating. The rating was downgraded by Zacks to “Sell” on Wednesday, September 2. The stock of Xenon Pharmaceuticals Inc (NASDAQ:XENE) earned “Buy” rating by Guggenheim on Monday, September 26. The rating was maintained by Jefferies on Wednesday, March 9 with “Buy”. On Tuesday, August 11 the stock rating was upgraded by Zacks to “Sell”. The stock of Xenon Pharmaceuticals Inc (NASDAQ:XENE) has “Buy” rating given on Friday, October 30 by Jefferies. The firm has “Sell” rating by Zacks given on Wednesday, August 19.

According to Zacks Investment Research, “Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.”

More recent Xenon Pharmaceuticals Inc (NASDAQ:XENE) news were published by: Quotes.Wsj.com which released: “News Xenon Pharmaceuticals Inc.XENE” on October 10, 2014. Also Globenewswire.com published the news titled: “Xenon Pharmaceuticals Appoints Dawn Svoronos to Its Board of Directors” on September 27, 2016. Globenewswire.com‘s news article titled: “Xenon Pharmaceuticals Achieves Milestone in Genentech Collaboration to …” with publication date: September 21, 2015 was also an interesting one.

XENE Company Profile

Xenon Pharmaceuticals Inc. (Xenon), incorporated on April 17, 2000, is a biopharmaceutical firm discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Firm has built a core platform, Extreme Genetics, enabling the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. Extreme Genetics involves the study of families where individuals exhibit inherited severe traits, or phenotypes. The Firm has an integrated platform that includes in-house capabilities for human genetics, small molecule drug discovery, as well as preclinical and clinical development. The Company’s development pipeline includes Glybera, TV-45070, GDC-0276 and GDC-0310, and XEN801.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment